title: Reticulated hyperpigmentation following chemotherapy for radiation-induced osteosarcoma.
authors.affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address: Catherine.a.necessary@vanderbilt.edu.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Necessary
authors.affiliation: Division of Dermatology, Department of Medicine, Vanderbilt University, Nashville, Tennessee.
authors.forename: David
authors.initials: D
authors.lastname: Roffwarg
authors.affiliation: Division of Dermatology, Department of Medicine, Vanderbilt University and VA Tennessee Valley Healthcare System, Nashville, Tennessee.
authors.forename: Darrel
authors.initials: D
authors.lastname: Ellis
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005047:Etoposide / Q000009:adverse effects; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D007069:Ifosfamide / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000209:etiology; D009918:Orbital Neoplasms / Q000188:drug therapy* / Q000209:etiology; D012516:Osteosarcoma / Q000188:drug therapy* / Q000209:etiology; D014221:Triamcinolone / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D014221:Triamcinolone; D005047:Etoposide; D007069:Ifosfamide; D008727:Methotrexate